There is evidence indicating that BMP antagonists and signaling pathway inhibitors block activation of SMAD1/5/8 signaling, and thereby reduce the incidence of subsequent events, including vascular inflammation and atherosclerosis[34,35]. This evidence concerns the gene SMAD1 and atherosclerosis.